Anixa Biosciences Valuation Multiples

Anixa Biosciences Overview

About Anixa Biosciences

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Founded

1982

HQ

Employees

4

Website

anixa.com

Sectors

BiopharmaceuticalsDiagnostics & GenomicsBioTech

Financials (LTM)

Revenue: —

Net Income: ($12M)

EV

$84M

Valuation Multiples

Multiples.vc

Start free trial

Anixa Biosciences Financials

Anixa Biosciences reported last 12-month revenue of —.

In the same LTM period, Anixa Biosciences generated had net loss of ($12M).

Anixa Biosciences P&L

In the most recent fiscal year, Anixa Biosciences reported revenue of — and EBITDA of ($12M).

Anixa Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Anixa Biosciences Stock Performance

Anixa Biosciences has current market cap of $99M, and enterprise value of $84M.

Anixa Biosciences' stock price is $2.96.

Anixa Biosciences Valuation Multiples

Anixa Biosciences trades at (7.2x) EV/EBITDA.

Anixa Biosciences Financial Valuation Multiples

As of March 18, 2026, Anixa Biosciences has market cap of $99M and EV of $84M.

Equity research analysts estimate Anixa Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Anixa Biosciences has a P/E ratio of (8.0x).

Anixa Biosciences Margins & Growth Rates

Anixa Biosciences' revenue in the last fiscal year declined by (100%).

Anixa Biosciences' revenue per employee in the last FY averaged $0.0M.

Anixa Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Diagnostics & Genomics comps.

Anixa Biosciences M&A Activity

Anixa Biosciences acquired XXX companies to date.

Last acquisition by Anixa Biosciences was on XXXXXXXX, XXXXX. Anixa Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Anixa Biosciences Investment Activity

Anixa Biosciences invested in XXX companies to date.

Anixa Biosciences made its latest investment on XXXXXXXX, XXXXX. Anixa Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).